Ces Urol 2019, 23(4):309-315 | DOI: 10.48095/cccu2019021

Hormone sensitive prostate cancer

Nikol Rušarová^1,2, Marie Bartoušková¹, Hana Študentová¹

¹ Onkologická klinika, Fakultní nemocnice v Olomouci

² Lékařská fakulta, Univerzita Palackého v Olomouci

Rušarová N, Bartoušková M, Študentová H. Hormone sensitive prostate cancer. Prostate cancer is the second most common cancer in men worldwide and its incidence rises with age. Although most cases of prostate cancer are diagnosed and treated in early stage of disease, almost 10 % of patients have evidence of metastatic prostate cancer at presentation, and others develop disseminated disease after their definitive treatment. Contemporary research has led to the development of multiple active treatment modalities for men with advanced disease including combination of docetaxel or abiraterone with androgen deprivation therapy.

Keywords: Prostate cancer, androgen deprivation therapy, docetaxel, abiraterone.

Received: February 24, 2019; Accepted: May 19, 2019; Prepublished online: April 1, 2019; Published: December 10, 2019